Cargando…

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two groups in the healthy population characterized b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Series, Jennifer, Garcia, Cédric, Levade, Marie, Viaud, Julien, Sié, Pierre, Ysebaert, Loïc, Payrastre, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821604/ https://www.ncbi.nlm.nih.gov/pubmed/30819914 http://dx.doi.org/10.3324/haematol.2018.207183

Ejemplares similares

Platelet Activation Is Limited during Transcatheter Aortic Valve Implantation in Patients on Aspirin Monotherapy and without per Procedural Clinical Complications
por: Dumonteil, Nicolas, et al.
Publicado: (2019)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis
por: Vardon Bounes, Fanny, et al.
Publicado: (2018)

Multicolor flow cytometry in clinical samples for platelet signaling assessment
por: Garcia, Cedric, et al.
Publicado: (2023)

Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders
por: Alessi, Marie-Christine, et al.
Publicado: (2020)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
por: Tuomi, Jari M., et al.
Publicado: (2021)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Platelets Are Critical Key Players in Sepsis
por: Vardon-Bounes, Fanny, et al.
Publicado: (2019)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Exploring the Role of PI3P in Platelets: Insights from a Novel External PI3P Pool
por: Mujalli, Abdulrahman, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
por: Morell, Anselm, et al.
Publicado: (2020)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Formation of ibrutinib solvates: so similar, yet so different
por: Jirát, Jan, et al.
Publicado: (2023)

Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19
por: Garcia, Cédric, et al.
Publicado: (2022)

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients
por: Protin, Caroline, et al.
Publicado: (2019)

Kinetics of mean platelet volume predicts mortality in patients with septic shock
por: Vardon-Bounes, Fanny, et al.
Publicado: (2019)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Phosphatidylinositol 3‐monophosphate: A novel actor in thrombopoiesis and thrombosis
por: Valet, Colin, et al.
Publicado: (2020)

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data
por: Le Louedec, Félicien, et al.
Publicado: (2021)

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
por: Cadot, Sarah, et al.
Publicado: (2020)

SHIP1 Controls Internal Platelet Contraction and α(IIb)β(3) Integrin Dynamics in Early Platelet Activation
por: Severin, Sonia, et al.
Publicado: (2023)

Platelet Versus Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?
por: Garcia, Cédric, et al.
Publicado: (2022)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Platelet P2Y(1) receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
por: Ribes, Agnès, et al.
Publicado: (2023)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

SARS-CoV-2 Omicron variant infection affects blood platelets, a comparative analysis with Delta variant
por: Garcia, Cédric, et al.
Publicado: (2023)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g1hf38ast8b41cjk3fp4i0e2ln